Top Markets
Coin of the day
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
주식 순위 #40225
Fusion Antibodies plc operates as a contract research organization (CRO),... Fusion Antibodies plc operates as a contract research organization (CRO), providing specialized services in the research, development, and manufacturing of recombinant proteins and antibodies. The company primarily focuses on solutions for oncology and infectious diseases, serving a global clientele across the United Kingdom, broader Europe, and North America. Its comprehensive suite of offerings encompasses monoclonal antibody discovery and advancement, antibody sequencing and engineering, and a distinct platform for antibody humanization and rational affinity maturation. Additionally, Fusion Antibodies provides recombinant protein expression, stable cell line development, and cGMP-compliant scale-up services. Clients span the pharmaceutical, biotechnology, and diagnostic sectors. Notably, the company maintains a collaborative partnership with Celonic AG. Established in 2000, Fusion Antibodies plc is headquartered in Belfast, United Kingdom.
주가
$0.1559364
마지막 동기화: 2026-09-18
시가총액
$195.17K
변동 (1일)
6.60%
변동 (1년)
-30.91%
국가
GB
거래 Fusion Antibodies plc (FAB)

카테고리

Fusion Antibodies plc (FAB)의 수익
Sep 2025 기준 수익 TTM: $-2.06M
Fusion Antibodies plc의 최신 재무 보고서에 따르면 회사의 현재 수익은 $-2.06M입니다. 2024년에 회사는 $-2.89M의 수익을 올렸으며 이는 2023년의 수익 $-3.53M과 증가입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Fusion Antibodies plc의 수익 기록 (2013 ~ 2026)
연말 수익
연도 수익 변화
2026 (TTM) $-2.06M -10.23%
2025 $-2.30M -20.56%
2024 $-2.89M -18.12%
2023 $-3.53M 101.40%
2022 $-1.75M 0.58%
2021 $-1.74M 30.88%
2020 $-1.33M -31.84%
2019 $-1.95M 95.89%
2018 $-997.05K -731.20%
2017 $157.96K 304.33%
2016 $39.07K -126.49%
2015 $-147.46K -26.55%
2014 $-200.78K -72.11%
2013 $-719.78K 0.00%
유사 기업 또는 경쟁사의 수익
회사 수익 수익 차이 국가
$5.27B -256,061.35%
US
$1.95B -94,754.12%
NL
$-3.09B 149,694.82%
US
$-4.02B 194,783.51%
AU
- -
CH